论文部分内容阅读
为观察血小板膜蛋白受体拮抗剂RGDS肽 (精 甘 天冬 丝氨酸肽 )作为溶栓的归巢装置 ,连接包有溶栓剂的脂质体 (LIP)的溶栓效果 ,用FeCl3复制腹主动脉血栓模型 ,各组自股静脉滴注 :①缓冲液 (PBS) ;② 5 .2万IU/kg尿激酶 (UKl) ;③ 1 5 .6万IU/kg尿激酶 (UKh) ;④ 5 .2万IU/kg尿激酶、脂质体与RGDS的混合物 (ULR) ;⑤包裹 5 .2万IU/kg尿激酶的脂质体与RGDS的混合物 (U LR) ;⑥包裹 5 .2万IU/kg尿激酶的脂质体与RGDS偶连物 (U L R)。发现 :UKh组和U L R组的血压与其他各组相比差异有显著性 (P <0 .0 5 )。ULR组〔( 2 7.1± 5 .7)mg〕及U LR组〔( 2 6.6± 6.1 )mg〕的血栓湿质量与U L R组〔( 2 0 .3± 5 .1 )mg〕相比差异有显著性 (P <0 .0 5 )。UKh及U L R组与其他各组相比血栓缩小。提示 :脂质体作为溶栓药物载体 ,经RGDS修饰后 ,具有较好的靶向性抗血栓作用。
In order to observe the thrombolytic effect of platelet membrane protein receptor antagonist RGDS peptide (Serum Aspartate Peptide) as a thrombolytic homing device, ligating the thrombolytic agent-containing liposomes (LIP), replicating abdominal aorta thrombosis with FeCl3 Model, each group from the femoral vein drip: ① buffer (PBS); ② 5200 IU / kg urokinase (UKl); ③ 1.56 million IU / kg urokinase (UKh); ④ 5.2 (IU / kg of urokinase, a mixture of liposomes and RGDS (ULR)); (5) a mixture of liposomes encapsulating 52,000 IU / kg of urokinase with RGDS kg of urokinase liposome and RGDS conjugate (ULR). It was found that there was a significant difference in blood pressure between UKh group and URL group compared with other groups (P <0.05). The difference of thrombus wet mass in ULR group 〔(21 7.1 ± 5 .7) mg〕 and U LR group 〔((2. 6.6 ± 6.1) mg〕〕 〔(20.3 ± 5.1) mg〕 in ULR group was Significance (P <0.05). Thrombosis was reduced in the UKh and URL groups compared with the other groups. Tip: Liposomes as a thrombolytic drug carrier modified by RGDS, has a good targeting antithrombotic effect.